ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 2.48K shares, a 98.58% decline from fiscal 2023.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 173.82K shares, a 218.74% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 54.53K shares, a 77.14% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-05 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 0.00 shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | |
| 2024-12-31 | 2.48K shares 10-K · filed 2025-03-10 | |
| 2023-12-31 | 24.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 173.82K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 71.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-12-31 | 3.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 54.53K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 50.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 82.37K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | -1.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 144.10K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 713.00 shares 10-Q · filed 2022-05-10 | 144.10K shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 31.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 238.51K shares 10-K · filed 2022-03-23 |
| 2021-09-30 | 111.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | |
| 2021-03-31 | 95.12K shares 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |